Immune Checkpoint Inhibitors Potentially Curative for Melanoma

Ten-year follow up from the CheckMate 067 and KEYNOTE-006 trials confirm that patients with advanced melanoma can achieve durable responses from treatment with the PD1 inhibitors nivolumab and pembrolizumab and that a lack of disease progression at 3 years is strong indicator of long-term survival. Dual checkpoint inhibition offers the deepest response, but monotherapy may be appropriate when aiming to avoid side effects.